BiotechTube
INFAI

INFAI

Cologne, Germany· Est.
infai1.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $500K

Overview

INFAI is a pioneer in non-invasive diagnostic tests using stable isotope technology, with a core focus on gastroenterology, metabolic, and cardiovascular diseases. The company's lead product, the Helicobacter Test INFAI, is an EMA-approved breath test registered in over 40 countries, establishing a commercial foundation. INFAI operates a Virtually Integrated Pharmaceutical Company (VIPCO) model with a lean internal team, supported by two advanced laboratories in Germany and the UK used for internal R&D and contract research. Its pipeline includes additional breath tests for gastric emptying and pancreatic function currently in preparation for regulatory approval.

GastroenterologyMetabolic DiseasesCardiovascular Diseases

Technology Platform

Development of non-invasive diagnostic tests using stable isotope tracers (e.g., ¹³C) analyzed by Isotope Ratio Mass Spectrometry (IRMS) for breath tests and Nuclear Magnetic Resonance (NMR) spectroscopy for metabolic profiling in urine and serum.

Funding History

1
Total raised:$500K
Grant$500K

Opportunities

The global trend towards non-invasive, cost-effective diagnostics creates significant demand for INFAI's breath tests as replacements for endoscopy.
Securing EMA approval for Gastromotal and Pancreo-Lip would diversify its product portfolio and open new revenue streams in functional GI testing.
The company's laboratory infrastructure and expertise position it well for growth in high-value contract research services for pharmaceutical clinical trials.

Risk Factors

Revenue is heavily reliant on a single product (Helicobacter Test INFAI), creating commercial concentration risk.
The regulatory approval process for its pipeline products (Gastromotal, Pancreo-Lip) is uncertain and poses a key development risk.
The company's virtual integrated model and small team create operational dependencies and key-person risk, particularly on founder Dr.
Sitke Aygen.

Competitive Landscape

INFAI competes in the H. pylori testing market with other breath test providers, stool antigen tests, and invasive endoscopic methods, where it holds a gold-standard position. In functional GI and metabolic testing, it faces competition from other specialized labs and emerging diagnostic technologies. Its main competitive advantages are first-mover status with EMA-approved stable isotope tests, proprietary expertise in IRMS/NMR, and an established international regulatory and distribution footprint.

More companies in Diagnostics & Precision Medicine →More companies in Germany →